Summary by Moomoo AI
Chimerix reported a Q2 2024 net loss of $20.7M ($0.23 per share), compared to $18.6M loss in Q2 2023. Research and development expenses increased to $18.4M from $16.9M year-over-year. The company maintained a strong balance sheet with $171.5M in available capital as of June 30, 2024.The Phase 3 ACTION study for dordaviprone in H3 K27M-mutant diffuse glioma remains on track, with first interim overall survival data expected in Q3 2025. The company has filed for Provisional Determination with Australia's Therapeutic Goods Administration, marking the second step toward potential Provisional Approval.ONC206's Phase 1 trials have reached dose level 10 of 11 planned levels, demonstrating dose proportional exposure with no dose-limiting toxicity to date. The company expects to complete enrollment in the remaining dose escalation cohorts by end of 2024, with assessment of objective responses planned for first half of 2025.
